TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06216262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Brushing teeth twice a day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Brushing teeth twice a day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Brushing teeth twice a day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Brushing teeth twice a day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novamin
Description: Brushing teeth twice a day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Propolis
Description: Brushing teeth twice a day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casein Phosphopeptide Amorphous Calcium Phosphate
Description: Following the procedure in the control group, it is applied to the tooth surface once a day for 3 minutes before going to bed at night for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate
Description: Following the procedure in the control group, mouthwash twice a day in the morning and evening for 8 weeks
Study: NCT05657171

Intervention type: DRUG
Intervention: cyproterone Acetate/Ethinyl Estradiol Combination
Description: cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
Study: NCT05732870

Intervention type: PROCEDURE
Intervention: Relevant orthopaedic surgery
Description: Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
Study: NCT06488833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Komtü Programme (Komtü)
Description: Mainly, 4 actions will take place:~* Training with reflective practice exercises. This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~* Healing spaces to generate a collective restorative experience, offering tools that facilitate emotional management~* Individual support for teachers to offer them resources, tools, and intervention strategies to help improve educational practice and the emotional and relational well-being of the school community~* Coaching for the school management team to help them establish some objectives together and offer them the necessary resources and tools so that they can achieve them successfully.
Study: NCT05199493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
Study: NCT06488833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Komtü Training and Reflective Practice
Description: This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~No other actions will take place in this group.
Study: NCT04414722

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BB-12
Description: Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BB-12
Description: Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Yogurt
Description: Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
Study: NCT05199493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
Study: NCT04644991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six minutes walking test
Description: Participants will be asked to walk as fast as they can for 6 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Six minutes walking test
Description: Participants will be asked to walk as fast as they can for 6 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Shame Kinesiology Tape
Description: Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
Study: NCT06061731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-frequency acupoint electrical stimulation
Description: In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
Study: NCT05685836

Intervention type: DRUG
Intervention: Bevacizumab Zirconium Zr-89
Description: See Arm description.
Study: NCT05991349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI129
Description: Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Study: NCT04234997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Description: Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant 0mg
Description: Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
Study: NCT06564350

Intervention type: DEVICE
Intervention: IMU (Inertial Measurement Unit) sensors
Description: IMU sensors track an object's acceleration and angular velocity over time and do not emit any electromagnetic fields or radiation. They use tiny masses and springs to measure the acceleration, as well as Hall effect materials to measure the magnetic fields. The force sensor changes its electric resistor value based on the force applied to the sensor surface.
Study: NCT06637384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid (HA)
Description: Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
Study: NCT05424523

Intervention type: DRUG
Intervention: Omalizumab
Description: Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
Study: NCT05665023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + modified FOLFIRINOX
Description: Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
Study: NCT06640465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ubiquinol + geranylgeraniol
Description: Combination of ubiquinol and geranylgeraniol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Geranylgeraniol
Description: Geranylgeraniol alone

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Ubiquinol alone

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ubiquinone
Description: Ubiquinone alone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06639139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogFun RG occupational therapy
Description: 21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self management
Study: NCT06643000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furmonertinib
Description: furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.
Study: NCT06641115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE Therapy
Description: Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
Study: NCT04118920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical insulin (4 units)
Description: N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical insulin (20 units)
Description: N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Artificial tears
Description: N=3, 40 microliters per drop
Study: NCT06638138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexband
Description: Artelon FLEXBAND is a commercially available, polycaprolactone polyurethane urea (PCL/PUUR) multipolymer synthetic knitted mesh that is used for soft tissue reinforcement procedures. The device is biocompatible and degradable and has been used as an augmentation device in over 50,000 Orthopedic tendon and ligament reconstructive procedures. The FLEXBAND kits contain the device and all of the instrumentation needed to insert the device.
Study: NCT06563570

Intervention type: OTHER
Group type: OTHER
Intervention: yoga (online)
Description: 8-week online yoga practices, 2 days a week
Study: NCT06637085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: low level laser therapy Probe laser device: (Laserklasse2M, EN60825-1, +A2:2002, W.L= 635-670nm, P\<6mW, German):low level laser therapy It will be used to stimulate vagus nerve .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy
Description: traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy
Description: traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACU TENSE
Description: Acu-TENS device (Digital TENS, EAF20, JERF20BD0604, add manufacturing country): It will be used to stimulate vagus nerve throug h the acupoint PC6 .
Study: NCT06186518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PİKSEÇ
Description: In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: The pediatric unit's PIVC insertion process will be routinely performed in routine care.
Study: NCT06525649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPT 2042
Description: NPT 2042 is a new drug being developed as an anti-seizure treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPT 2042
Description: NPT 2042 is a new drug being developed as an anti-seizure treatment.
Study: NCT05280210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTC drug screening
Description: PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
Study: NCT04634799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TM5614
Description: TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
Study: NCT06525649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPT 2042
Description: NPT 2042 is a new drug being developed as an anti-seizure treatment.
Study: NCT06149312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Intervention
Description: Standardized interview based on The letter Project (Stanford Medicine) and Questions Prompt List
Study: NCT04634799

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
Study: NCT06558006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Predimenol tablet
Description: 2 tablets of Predimenol (400 mg Predimenol) will be taken with 220 mL of water (one glass of water).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Predimenol tablet + Placebo tablet of Predimenol
Description: 1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo will be taken with 220 mL of water (one glass of water).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet of Predimenol
Description: 2 tablets of placebo tablet of Predimenol will be taken with 220 mL of water (one glass of water).
Study: NCT04414722

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Yogurt
Description: Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
Study: NCT05630495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study: NCT04391309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD14
Description: 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
Study: NCT05592483

Intervention type: OTHER
Intervention: None (Observational Study)
Description: Not Applicable since observational study

Intervention type: OTHER
Intervention: None (Observational Study)
Description: Not Applicable since observational study
Study: NCT06210685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Continuous Effusion Shunt implantation
Description: The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
Study: NCT06569758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci098
Description: subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GenSci098 Placebo
Description: In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, GenSci098 and GenSci098 will be given on Day 1 and Day 85
Study: NCT04208490

Intervention type: OTHER
Group type: OTHER
Intervention: HN-STAR Intervention
Description: The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
Study: NCT05829239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Intramuscular injection weekly for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection weekly for 8 weeks
Study: NCT06579417

Intervention type: DIAGNOSTIC_TEST
Intervention: RSI MRI
Description: In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients' images are read separately by two expert radiologists at the center, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients' future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.
Study: NCT04391309

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously on Days 1-4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remdesivir
Description: Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remdesivir
Description: Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
Study: NCT06217029

Intervention type: OTHER
Intervention: physiotherapy and maxillary traction
Description: 1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release

Intervention type: OTHER
Intervention: physiotherapy and maxillary traction
Description: 1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release
Study: NCT05776706

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AR-based navigation
Description: The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)
Study: NCT06488599

Intervention type: RADIATION
Intervention: Peri-apical radiographs on the implants
Description: Peri-apical radiographs on the implants supporting the prosthesis

Intervention type: RADIATION
Intervention: Peri-apical radiographs on the implants
Description: Peri-apical radiographs on the implants supporting the prosthesis
Study: NCT04811287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release with Platelet-Rich Plasma
Description: CTR is performed with adjuvant PRP placed intra-operatively.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Carpal Tunnel Release without Platelet-Rich Plasma
Description: CTR is performed without adjuvant PRP placed intra-operatively.
Study: NCT05822440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Single oral dose (period 1) or co-administered with itraconazole (period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Single oral dose (period 1) or co-administered with itraconazole (period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Interacting drug which will be given for 7 days in period 2
Study: NCT06567015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-241
Description: Film-coated tablet~Route of administration: Oral
Study: NCT06094140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m2 intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate (leucovorin)
Description: 50mg as an intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Description: 6mg by subcutaneous injection to be given on day 3 of each cycle.
Study: NCT05365386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.